New 'Lilly Gateway Labs' Hub
To Be Located at C-Lab Outside, Scheduled for Completion Next Year

Samsung Biologics announced on March 10 that it has signed an open innovation partnership with Eli Lilly and Company in the United States to foster promising domestic biotech companies.

Samsung Biologics Plant 4 exterior view. Samsung Biologics

Samsung Biologics Plant 4 exterior view. Samsung Biologics

View original image

Under this agreement, the two companies will establish a new hub for Lilly’s open innovation program, "Lilly Gateway Labs (LGL)," in Songdo International City, Incheon. Launched by Lilly in 2019, LGL is a program aimed at discovering and nurturing outstanding biotech companies. It not only provides state-of-the-art office and laboratory facilities, but also supports the growth of emerging biotech startups through research and development (R&D) collaboration, mentoring, direct investment, and assistance in attracting external investments.


The establishment of the LGL hub is expected to serve as a catalyst for expanding global opportunities for promising Korean biotech companies. Since its inception, the total investment raised by LGL participating companies is reported to have exceeded USD 3 billion (approximately KRW 441.21 billion).



The new LGL hub is scheduled to be housed at the new open innovation center, "C-Lab Outside," which will be completed next year at the Samsung Biologics Second Bio Campus in Songdo, Incheon. The two companies plan to jointly operate the center, including the selection and nurturing of 30 resident companies at C-Lab Outside, as well as pursue various collaborative initiatives to invigorate the K-Bio ecosystem.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing